{"disease":{"id":"parkinson-s-disease","name":"Parkinson's disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":34,"pipeline_drug_count":0,"trial_count":22},"drugs":{"marketed":[{"drug_id":"pimavanserin","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuplazid","generic_name":"PIMAVANSERIN","company_name":"Acadia Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":70,"revenue":"600","mechanism":"Nuplazid works by blocking the action of a specific chemical messenger in the brain called serotonin."},{"drug_id":"bia-9-1067","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ongentys","generic_name":"BIA 9-1067","company_name":"Neurocrine Biosciences","drug_phase":"marketed","molecular_target":"Catechol O-methyltransferase","drug_class":"Catechol-O-Methyltransferase Inhibitor [EPC]","quality_score":59,"revenue":"200","mechanism":"Ongentys works by blocking the enzyme that breaks down dopamine, allowing more dopamine to be available in the brain."},{"drug_id":"cycrimine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pagitane","generic_name":"CYCRIMINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"levodopa","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inbrija","generic_name":"LEVODOPA","company_name":"Merz","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Fyn","drug_class":"Aromatic Amino Acid [EPC]","quality_score":10,"revenue":null,"mechanism":"Levodopa works by crossing the blood-brain barrier and being converted into dopamine, a neurotransmitter that helps regulate movement and coordination."},{"drug_id":"foscarbidopa","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FOSCARBIDOPA","company_name":"AbbVie GK","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":"Foscarbidopa works by increasing the levels of dopamine in the brain, a neurotransmitter that is often deficient in people with Parkinson's disease."},{"drug_id":"foslevodopa","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FOSLEVODOPA","company_name":"AbbVie GK","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":"Foslevodopa works by increasing the levels of levodopa in the brain, which helps to alleviate symptoms of Parkinson's disease."},{"drug_id":"carbidopa","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sinemet Cr","generic_name":"CARBIDOPA","company_name":"Aton","drug_phase":"marketed","molecular_target":"Lysine-specific demethylase 4E","drug_class":"Aromatic Amino Acid [EPC]","quality_score":54,"revenue":null,"mechanism":"Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, relieving Parkinson's disease symptoms."},{"drug_id":"selegiline","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Selegiline Hydrochloride","generic_name":"SELEGILINE","company_name":"Somerset","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B","drug_class":"Monoamine Oxidase Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"apomorphine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apokyn","generic_name":"APOMORPHINE","company_name":"Mdd Us","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bromocriptine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parlodel","generic_name":"BROMOCRIPTINE","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Ergot Derivative","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"droxidopa","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Northera","generic_name":"DROXIDOPA","company_name":"Lundbeck Na Ltd","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Catecholamine","quality_score":10,"revenue":null,"mechanism":"Northera works by increasing the levels of certain neurotransmitters in the brain, such as norepinephrine, to help regulate blood pressure and movement."},{"drug_id":"trihexyphenidyl-hydrochloride","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"rotigotine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupro","generic_name":"ROTIGOTINE","company_name":"UCB","drug_phase":"marketed","molecular_target":"dopamine receptors","drug_class":"Nonergot Dopamine Agonist [EPC]","quality_score":65,"revenue":null,"mechanism":"Rotigotine stimulates dopamine receptors in the brain, which may help treat Parkinson's disease and Restless Legs Syndrome."},{"drug_id":"entacapone","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comtan","generic_name":"ENTACAPONE","company_name":"Orion Pharma","drug_phase":"marketed","molecular_target":"Catechol O-methyltransferase","drug_class":"Catechol-O-Methyltransferase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Comtan works by blocking the enzyme catechol-O-methyltransferase, which breaks down dopamine in the brain."},{"drug_id":"apokyn","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"APOKYN","company_name":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Dopaminergic Agonist","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"lodosyn","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lodosyn","company_name":"University of Miami","drug_phase":"discontinued","molecular_target":"Lysine-specific demethylase 4E, Aromatic-L-amino-acid decarboxylase, Tyrosine-protein kinase Fyn","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"exelon","indication_name":"Dementia associated with Parkinson's Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Exelon","company_name":"US Department of Veterans Affairs","drug_phase":"marketed","molecular_target":"Acetylcholinesterase, Cholinesterase, Acetylcholine receptor subunit epsilon","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"rivastigmine","indication_name":"Dementia associated with Parkinson's Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exelon","generic_name":"rivastigmine","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Acetylcholinesterase, Cholinesterase, Acetylcholine receptor subunit epsilon","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"ropinirole","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Requip","generic_name":"ropinirole","company_name":"GSK","drug_phase":"marketed","molecular_target":"D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"cogentin","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cogentin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"northera","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Northera","company_name":"The Cooper Health System","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Adrenergic receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"trihexyphenidyl","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"talipexole","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Domin","generic_name":"TALIPEXOLE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"requip","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Requip","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"procyclidine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kemadrine","generic_name":"PROCYCLIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"biperiden","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Akineton","generic_name":"BIPERIDEN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"istradefylline","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nourianz","generic_name":"ISTRADEFYLLINE","company_name":"Kyowa Kirin","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"CYP3A4 Substrates","quality_score":70,"revenue":null,"mechanism":"Nourianz works by blocking the adenosine receptor A2a, which helps to increase dopamine levels in the brain."},{"drug_id":"amantadine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gocovri","generic_name":"AMANTADINE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"benzatropine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cogentin","generic_name":"benzatropine","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"safinamide","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xadago","generic_name":"SAFINAMIDE","company_name":"Mdd Us","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B","drug_class":"Monoamine Oxidase Type B Inhibitor","quality_score":65,"revenue":null,"mechanism":"Xadago works by blocking the enzyme amine oxidase [flavin-containing] B, which breaks down dopamine in the brain."},{"drug_id":"rasagiline","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azilect","generic_name":"RASAGILINE","company_name":"Teva","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6","drug_class":"Monoamine Oxidase Inhibitor","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"gocovri","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GOCOVRI","company_name":"Oregon Health and Science University","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ongentys","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ongentys","company_name":"Bial - Portela C S.A.","drug_phase":"marketed","molecular_target":"Catechol O-methyltransferase, Catechol O-methyltransferase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amantadin","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amantadin","company_name":"Centre Hospitalier Universitaire de Nice","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zelapar","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zelapar","company_name":"Baylor College of Medicine","drug_phase":"marketed","molecular_target":"Alpha-synuclein, Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"foslevodopa","indication_name":"Motor fluctuations in advanced Parkinson’s disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FOSLEVODOPA","company_name":"AbbVie GK","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":"Foslevodopa works by increasing the levels of levodopa in the brain, which helps to alleviate symptoms of Parkinson's disease."},{"drug_id":"bromocriptin","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bromocriptin","company_name":"University Hospital, Bonn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pramipexole","indication_name":"Parkinson's Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PRAMIPEXOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":11,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":38,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04701177","title":"Digitally-enhanced, Decentralized, Multi-omics Observational Cohort","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Greece 2021 Committee","has_results":false},{"nct_id":"NCT03285230","title":"The French E3N Prospective Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT01399411","title":"Agricultural Health Study Follow-up","phase":"","overall_status":"COMPLETED","enrollment_count":89656,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT06209515","title":"Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61292,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT04994015","title":"Parkinson's Foundation PD GENEration Genetic Registry","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Parkinson's Foundation","has_results":false},{"nct_id":"NCT03866603","title":"Rostock International Parkinson's Disease Study (ROPAD)","phase":"","overall_status":"COMPLETED","enrollment_count":20112,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT03945968","title":"The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Russian Federation of Anesthesiologists and Reanimatologists","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT04375280","title":"Evaluation of Impaired Mobility in Chronic Illness Constitution of a Cohort","phase":"NA","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT05413291","title":"Natural History Protocol for Movement Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT04214509","title":"LIPAD - LRRK2 International Parkinson's Disease Study","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"University of Luebeck","has_results":false},{"nct_id":"NCT00367900","title":"Parkinson's Genes and Environment Study","phase":"","overall_status":"COMPLETED","enrollment_count":3100,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT04957420","title":"The Practical Effect of Neupro","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT03924414","title":"Trial of Parkinson's And Zoledronic Acid","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2650,"lead_sponsor_name":"California Pacific Medical Center Research Institute","has_results":false},{"nct_id":"NCT02881099","title":"Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)","phase":"","overall_status":"COMPLETED","enrollment_count":2614,"lead_sponsor_name":"South Glasgow University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT05209698","title":"Self-Management Behaviors of Arabs and Jews With Parkinson's Disease and Their Associations With Health Outcomes","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"University of Haifa","has_results":false},{"nct_id":"NCT00136721","title":"Parkin Mutations and Their Functional Consequences","phase":"","overall_status":"COMPLETED","enrollment_count":2500,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT03837067","title":"Use and Misuse of Domperidone in Parkinson's Disease in France - Dump Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":2300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03233646","title":"Retinal Imaging in Neurodegenerative Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06949865","title":"AI-Enhanced Optimization of Acute Levodopa Challenge Test","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT04057794","title":"PDGeneration: Mapping the Future of Parkinson's Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1982,"lead_sponsor_name":"Parkinson's Foundation","has_results":false},{"nct_id":"NCT00044590","title":"Parkinson's Diseases Susceptibility Genes and Pesticides","phase":"","overall_status":"COMPLETED","enrollment_count":1870,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT04023201","title":"Nocturnal Symptoms and Quality of Life in Patients With Parkinson's Disease in Shanghai","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04270604","title":"Biological Sample Collection for Research and Biobanking","phase":"","overall_status":"TERMINATED","enrollment_count":1279,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT01019343","title":"Physiological Investigations of Movement Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":1273,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT03994328","title":"An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD","phase":"","overall_status":"COMPLETED","enrollment_count":1235,"lead_sponsor_name":"Zambon SpA","has_results":false},{"nct_id":"NCT03727139","title":"Rasagiline Tablets Special Drug Use-Results Survey \"Survey on Long-term Safety\"","phase":"","overall_status":"COMPLETED","enrollment_count":1021,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT06377033","title":"Using the EHR to Advance Genomic Medicine Across a Diverse Health System","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT07222605","title":"Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"eQ8Health Corporation d/b/a CareONE Concierge","has_results":false},{"nct_id":"NCT07174310","title":"A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01215227","title":"An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":839,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02906488","title":"Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":839,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04919356","title":"Parkinson's Disease G2019S LRRK2 Genetic Testing Program","phase":"","overall_status":"TERMINATED","enrollment_count":836,"lead_sponsor_name":"Escape Bio, Inc.","has_results":false},{"nct_id":"NCT06980064","title":"Wearable Devices Assist in the Detection, Screening, and Management of Major Diseases in Middle-aged and Elderly Populations","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03516994","title":"Reducing Disparities in the Quality of Advance Care Planning for Older Adults","phase":"NA","overall_status":"COMPLETED","enrollment_count":790,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03076671","title":"More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":783,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT07392411","title":"Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers","phase":"","overall_status":"RECRUITING","enrollment_count":720,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT07353463","title":"Shanghai Clinical Cohort - Parkinson's Disease (Reserve)","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT07386015","title":"Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Tianjin Huanhu Hospital","has_results":false},{"nct_id":"NCT06984757","title":"Mid-frontal Delta/Theta and Cognitive Control","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":635,"lead_sponsor_name":"Nandakumar Narayanan","has_results":false},{"nct_id":"NCT05222386","title":"Community Outreach for Palliative Engagement -- Parkinson Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":632,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT03670953","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":630,"lead_sponsor_name":"Impax Laboratories, LLC","has_results":true},{"nct_id":"NCT06389032","title":"PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":622,"lead_sponsor_name":"Rush University Medical Center","has_results":false},{"nct_id":"NCT06993142","title":"Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT06072287","title":"The Living With a Long-Term Condition Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT07214974","title":"Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Noah Tech, Corp.","has_results":false},{"nct_id":"NCT05895019","title":"Effects of Propofol on Brain Function in Patients With Parkinson's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}